培哚普利联合比索洛尔治疗慢性心力衰竭97例临床观察

Efficacy of perindopril and bisoprolol in the trentment of 97 cases of chronic heart failure

目的：观察97例慢性心力衰竭（心力衰竭）患者接受标准化药物治疗的疗效及临床经验。方法：慢性心力衰竭患者97例,心功能NYHA分级1－3级,用药前1周均接受心电图、胸片、超声心动图检查,并对心功能再次作临床评价。除心功能NYHA1级患者不接受利尿剂治疗外,其他入选病例均接受培哚普利加比索洛尔药物治疗,并于药物治疗后的1周,2周,4周,8周及6个月时门诊复诊。检测血压、血钾和肾功能,并对药物疗效作阶段性评价。结果：97例患者知情同意均接受了培哚普利加比索洛尔治疗,其中53例患者期间使用了利尿剂（呋塞米19例,氢氯噻嗪34例）,11例慢性心力衰竭并慢性房颤患者合用了地高辛。观察随访期间,2例发生猝死,9例因症状加重而住院,5例于2周后失访。最终81例患者观察结果显示,标准化药物治疗后症状明显改善,住院率下降,死亡率降低。结论：正规标准化药物治疗能显著改善慢性心力衰竭患者的临床症状进而改善心功能,提高患者的生活质量,进一步降低住院率、致残率及死亡率。

Objective 97 patients with chronic heart failure （CHF） who were observed received standard treatment of drug efficacy and clinical experience. Methods Doctor had selected patient with chronic heart failure patient diagnosed 97 cases, NYHA heart function classification Ⅰ-Ⅲ grade, 1 Week before treatment underwent ECG,chest radiograph,echo cardiography, And again for clinical evaluation of cardiac function, in addition to cardiac function in patients with NYHA grade I did not accept the diuretic treatment, Other selected patients who were given perindopril ＋ bisoprolol medication, And medication treatment for one week, two week, four weeks, eight weeks and 6 months out -patient referral ,monitoring of blood pressure,heart rate,serum potassium and renal function ,And to make periodic evaluation of drug efficacy. Results 97 cases who were informed consent of patients received perindopril and bisoprolol treatment. 53 patients used di- uretics （furosemide 19 cases, 34 cases of hydrochlorothiazide）, 11 patients with chronic heart failure and chronic atrial fibrillation combined with a digoxin. During follow - up, 2 cases of sudden death, 9 patients hospitalized because of increased symptoms, 5 lost after 2 weeks. Observation of 81 patients eventually standardized drug treatment showed significant improvement in symptoms,The rate of hospitalization and mortality decreased. Conclusion Formal standard drug therapy can significantly improve the amount of clinical symptoms in patients with chronic heart failure ,in order to improve cardiac function, Improve patient quality of life, Further reduce the hospitalization rate, Reduce mortality.